Tuesday, December 10, 2013 (7:30 AM - 12:00 PM)
Learning Objectives: Discover a unique strategy of adding additional arms to your FIH study to gain an Initial read into Formulation Performance.
Presented by: Dr Daria Stypinski, BSc (Pharm), PhD, Senior Managing Principal Scientist and Market Segment Team Leader, Clinical Pharmacology Sciences
Learning Objectives: Present and discuss challenges in the early clinical assessment of BioSimilar Drugs
Presented by: Dr. Fred Pritchard, VP, Global Drug Development, Celerion
Who Should Attend: Those involved in Phase I Clinical Development; Clinical Project Managers; Clinical Pharmacologists; and Science and Medical Officers
Celerion, an expert in Applied Translational Medicine, applies their expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
1551 Eastlake Ave E, 1st Floor
Seattle, WA 98102 United States
© 2012 Washington Biotechnology & Biomedical Association